304 related articles for article (PubMed ID: 36632222)
21. ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9.
Li Y; Yan B; Wang X; Li Q; Kan X; Wang J; Sun Y; Wang P; Tian L; Liu M
J Cell Mol Med; 2022 Jan; 26(2):385-398. PubMed ID: 34850551
[TBL] [Abstract][Full Text] [Related]
22. ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation.
Shao Y; Liu Z; Song X; Sun R; Zhou Y; Zhang D; Sun H; Huang J; Wu C; Gu W; Zheng X; Jiang J
Clin Transl Med; 2023 Jul; 13(7):e1318. PubMed ID: 37381158
[TBL] [Abstract][Full Text] [Related]
23. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
24. ALKBH5 facilitates CYP1B1 mRNA degradation via m6A demethylation to alleviate MSC senescence and osteoarthritis progression.
Ye G; Li J; Yu W; Xie Z; Zheng G; Liu W; Wang S; Cao Q; Lin J; Su Z; Li D; Che Y; Fan S; Wang P; Wu Y; Shen H
Exp Mol Med; 2023 Aug; 55(8):1743-1756. PubMed ID: 37524872
[TBL] [Abstract][Full Text] [Related]
25. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
[TBL] [Abstract][Full Text] [Related]
26. RNA demethylase ALKBH5 inhibits TGF-β-induced EMT by regulating TGF-β/SMAD signaling in non-small cell lung cancer.
Sun Z; Su Z; Zhou Z; Wang S; Wang Z; Tong X; Li C; Wang Y; Chen X; Lei Z; Zhang HT
FASEB J; 2022 May; 36(5):e22283. PubMed ID: 35344216
[TBL] [Abstract][Full Text] [Related]
27.
Zhao X; Zhao Z; Xie H; Gao W; Ye C
Discov Med; 2024 Jan; 36(180):61-70. PubMed ID: 38273746
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.
Zhang C; Zhi WI; Lu H; Samanta D; Chen I; Gabrielson E; Semenza GL
Oncotarget; 2016 Oct; 7(40):64527-64542. PubMed ID: 27590511
[TBL] [Abstract][Full Text] [Related]
29. ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.
Li W; Huang G; Wei J; Cao H; Jiang G
Mol Cell Biochem; 2023 Apr; 478(4):729-741. PubMed ID: 36070054
[TBL] [Abstract][Full Text] [Related]
30. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
[TBL] [Abstract][Full Text] [Related]
31. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
32. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
33. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
34. m
Jin D; Guo J; Wu Y; Yang L; Wang X; Du J; Dai J; Chen W; Gong K; Miao S; Li X; Sun H
Mol Cancer; 2020 Feb; 19(1):40. PubMed ID: 32106857
[TBL] [Abstract][Full Text] [Related]
35. m
Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
[TBL] [Abstract][Full Text] [Related]
36. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
37. ALKBH5-mediated m
Hao L; Yin J; Yang H; Li C; Zhu L; Liu L; Zhong J
Aging (Albany NY); 2021 Jan; 13(3):4045-4062. PubMed ID: 33428593
[TBL] [Abstract][Full Text] [Related]
38. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
[TBL] [Abstract][Full Text] [Related]
39. Distinct RNA
Toh JDW; Crossley SWM; Bruemmer KJ; Ge EJ; He D; Iovan DA; Chang CJ
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25284-25292. PubMed ID: 32989163
[TBL] [Abstract][Full Text] [Related]
40. ALKBH5-mediated m6A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription.
Liang L; Zhu Y; Li J; Zeng J; Wu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):261. PubMed ID: 36028854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]